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Summary
 
Naive T cells recirculate mainly within the secondary lymphoid compartment, but once acti-
vated they can enter peripheral tissues and perform effector functions. To activate naive T cells,
foreign antigens must traffic from the site of infection to the draining lymph nodes, where they
can be presented by professional antigen presenting cells. For major histocompatibility complex
class I–restricted presentation to CD8
 
1
 
 T cells, this can occur via the cross-presentation path-
way. Here, we investigated the conditions allowing antigen access to this pathway. We show
that the level of antigen expressed by peripheral tissues must be relatively high to facilitate
cross-presentation to naive CD8
 
1
 
 T cells. Below this level, peripheral antigens did not stimu-
late by cross-presentation and were ignored by naive CD8
 
1
 
 T cells, although they could sensi-
tize tissue cells for destruction by activated cytotoxic T lymphocytes (CTLs). Interestingly,
CTL-mediated tissue destruction facilitated cross-presentation of low dose antigens for activa-
tion of naive CD8
 
1
 
 T cells. This represents the first in vivo evidence that cellular destruction
can enhance access of exogenous antigens to the cross-presentation pathway. These data indi-
cate that the cross-presentation pathway focuses on high dose antigens and those released dur-
ing tissue destruction.
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1
 
 CTLs, which recognize antigens presented by
class I molecules encoded by the MHC, are important
for immunity to viruses and other intracellular pathogens.
Access to the class I–restricted presentation pathway gener-
ally requires that protein antigens are expressed within the
cytoplasmic compartment of the presenting cell (1). This
pathway has been described as the endogenous pathway,
contrasting it with the class II–restricted pathway, which
generally presents exogenous (extracellular) antigens.
Despite the apparent demarcation between the class I–
and class II–restricted pathways, Bevan demonstrated over
20 years ago that under certain circumstances exogenous
antigens can access the class I–restricted pathway (2). Such
“cross-presentation” has now been observed in many
tolerogenic as well as immunogenic responses (2–14). It has
been proposed that the role of cross-presentation is to pro-
tect against tissue-tropic viruses that, in the absence of
infection of professional APCs, would not access the class
I–restricted pathway of these cells, and would therefore fail
to prime naive CTLs (15, 16). In this model, the advantage
of the cross-priming APC is that it can capture antigens
from virus-infected tissues, process them into the class I path-
way, and present them to naive CTLs in the draining LNs.
Recently, we used transgenic expression of the model anti-
gen OVA to provide direct evidence that peripheral tissue an-
tigens can be transported to draining LNs for class I–restricted
presentation by a bone marrow–derived APC (10). In this
earlier study, transgenic mice expressing membrane-bound
OVA (mOVA) under the control of the rat insulin promoter
(RIP) in the pancreas, kidney, and thymus were injected
with class I–restricted, OVA-specific, CD8
 
1
 
 T cells from
the OT-I transgenic line. When responses were assessed
several days later, OT-I cells had proliferated and accumu-
lated in nodes draining OVA-expressing tissues. Further-
more, antigen was presented by a bone marrow–derived
cell, implying that tissue antigens were captured and then
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processed by a professional APC (the cross-presenting
APC).
In this report, we examined the requirements for antigen
entry into the cross-presentation pathway, using various
transgenic mice expressing the model antigen OVA at dif-
ferent levels in the pancreas. Our studies show that only
relatively high dose antigens constitutively gain effective
entry into this pathway, but that cellular destruction may
enhance access of low dose antigens. The implications of
these findings with respect to immunity and tolerance are
discussed.
 
Materials and Methods
 
Mice.
 
All mice were bred and maintained at the Walter and
Eliza Hall Institute for Medical Research. OT-I, RIP-mOVA,
and RIP-OVA
 
lo
 
 transgenic mice have been described previously
(10, 17). Note that RIP-OVA
 
lo
 
 mice were referred to previously
as RIP-OVA mice (17). RIP-OVA
 
hi
 
 mice were generated using
the same techniques.
 
Adoptive Transfer and FACS
 
Ò
 
 Analysis.
 
Preparation and adop-
tive transfer of OT-I cells, 5,6-carboxy-succinimidyl-fluorescein-
ester (CFSE)-labeling, and analysis on a FACScan
 
Ò
 
 (Becton
Dickinson, Mountain View, CA) were carried out as described
previously (11, 18, 19).
 
 
 
PE-conjugated anti-CD8 (YTS 169.4)
was from Caltag Labs (South San Francisco, CA). Dead cells were
excluded by propidium iodide staining.
 
Activation of OT-I Cells In Vitro.
 
OT-I cells were activated by
culturing 10
 
7
 
 OT-I spleen cells for 5 d in 30 ml of medium with
10
 
8
 
 irradiated (1,500 cGy) B6 spleen cells previously coated for 30
min at 5 
 
3 
 
10
 
7
 
 cell/ml with 0.2 
 
m
 
g/ml OVA
 
257–264
 
 peptide.
Stimulator cells were washed once after peptide pulsing. Culture
medium consisted of mouse tonicity RPMI1640, 10% fetal calf
serum, 2 mM glutamine, 5 
 
3 
 
10
 
2
 
5
 
 M 2-ME, and antibiotics.
 
Results
 
Antigen Dose Affects Cross-presentation.
 
To examine the
role of antigen dose in cross-presentation of tissue antigens,
two lines of transgenic mice were produced expressing dif-
ferent amounts of secreted OVA in the 
 
b
 
 cells of the pan-
creas, under the control of the RIP. These were termed
RIP-OVA
 
lo
 
 and RIP-OVA
 
hi
 
 mice. RIP-OVA
 
hi
 
 mice ex-
pressed sufficient OVA to show weak OVA-specific stain-
ing immunohistologically, whereas OVA expression by
RIP-OVA
 
lo
 
 mice could not be detected by this technique
(Fig. 1). However, expression of OVA by the latter line has
been shown previously using alternative approaches (refer-
ence 17 and see Fig. 3).
To investigate the effect of antigen dose on the access of
peripheral tissue antigens to the cross-presentation pathway,
naive CD8
 
1
 
 cells from the OT-I cell line were labeled with
the fluorescent dye CFSE (11, 18, 19) and injected intrave-
nously into both RIP-OVA
 
lo
 
 and RIP-OVA
 
hi
 
 mice. 3 d
later, the pancreatic (draining) and inguinal (nondraining)
LNs were examined for proliferating OT-I cells. When
CFSE-labeled cells proliferate, their fluorescence is equally
distributed between daughter cells resulting in a 2
 
n
 
-fold re-
duction in fluorescence intensity, where
 
 n 
 
is the number of
cell divisions. Adoptive transfer of CFSE-labeled OT-I
cells revealed that only RIP-OVA
 
hi
 
 mice were able to sup-
ply sufficient OVA to the cross-presentation pathway for
stimulation of naive OT-I cells in the pancreatic draining
LN (Fig. 2). These findings indicated that antigen expres-
Figure 1. OVA expression by pancreatic islets of transgenic mice. RIP-
mOVA mice (A), RIP-OVAlo mice (B), and RIP-OVAhi mice (C) were
stained for OVA using a rabbit anti-OVA antiserum, obtained by immu-
nizing rabbits with whole OVA (Grade V; Sigma Chemical Co., St.
Louis, MO) and horseradish peroxidase–conjugated swine anti–rabbit Ig
(DAKO, A/S, Glostrup, Denmark) as previously described (10). Note
that secreted OVA was very difficult to detect immunohistologically and
could only be demonstrated in the RIP-OVAhi line. RIP-mOVA mice,
which express a membrane-bound form of OVA in their islet, were in-
cluded as a positive control to show that this technique efficiently detects
OVA when it is not secreted. 
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sion above a critical level was required for antigen access to
the cross-presentation pathway. Neither line of mice be-
came diabetic when 5 
 
3 
 
10
 
6
 
 naive OT-I cells were adop-
tively transferred (data not shown).
 
Lower Levels of Tissue Antigen Expression that Do Not Facil-
itate Cross-presentation May Still Be of Physiological Relevance.
 
To determine whether the lower antigen dose expressed by
RIP-OVA
 
lo
 
 mice was of physiological relevance, we asked
whether activated CTLs, which have the capacity to enter
tissues, could recognize tissue cells expressing this low dose
of OVA. RIP-OVA
 
lo
 
 mice were injected with 10
 
7
 
 acti-
vated OT-I cells (generated by stimulation with antigen for
5 d in vitro) and then examined for the onset of diabetes
(Fig. 3). As a control, RIP-OVA
 
hi
 
 mice were also injected
with activated cells. Diabetes induction in the RIP-OVA
 
lo
 
mice indicated that the low level of OVA expressed by
these mice was sufficient to target islet 
 
b
 
 cells for recogni-
tion and destruction by activated CTLs. Thus, although
only high doses of OVA stimulated naive CTLs via the
cross-presenting pathway, lower doses were able to target
peripheral tissues for destruction by activated CTLs.
 
Tissue Destruction Facilitates Cross-presentation of Low Dose
Antigens.
 
If, as proposed, the cross-presentation pathway
is important for virus immunity, then it makes sense to fo-
cus on high dose antigens, since virus proteins are likely to
be produced in relatively large amounts during replicative
infections. An alternative way to bias the immune system
towards detecting virus antigens would be to preferentially
present antigens released during tissue destruction. With
this in mind, we asked whether destruction of 
 
b
 
 cells ex-
pressing low doses of OVA would improve antigen access
to the cross-presentation pathway. RIP-OVA
 
lo
 
 mice were
injected intravenously with in vitro–activated OT-I cells
and then 4 d later with CFSE-labeled naive OT-I cells or
B6 CD8
 
1
 
 T cells. The activated OT-I cells were used to
specifically cause islet destruction (as shown by the induc-
tion of diabetes in Fig. 3), and the CFSE-labeled cells were
used to measure the response of naive cells to antigen
(OVA) cross-presented in the draining LNs. 3 d after the
transfer of CFSE-labeled cells (that is, 7 d after the transfer
of activated CTLs), the LNs of these mice were recovered
and examined for proliferating cells (Fig. 4). As shown, na-
ive CFSE-labeled OT-I cells proliferated in the pancreatic
(draining) LNs of RIP-OVA
 
lo
 
 mice that were previously
injected with activated CTLs (Fig. 4, 
 
C
 
 and 
 
D
 
), but not in
untreated mice (Fig. 4, 
 
A
 
 and 
 
B
 
), even if left for up to 8 d
in vivo
 
 
 
(data not shown). By contrast, CFSE-labeled B6
CD8
 
1
 
 T cells did not proliferate in the pancreatic LNs in
either the presence (Fig. 4, 
 
E
 
 and 
 
F
 
) or absence (data not
shown) of activated CTLs
 
. 
 
Thus, an antigen-specific re-
sponse of OT-I cells was observed after the destruction of
 
b
 
 cells by activated CTLs. When proliferation was exam-
ined in bm1
 
®
 
RIP-mOVA.B6 bone marrow chimeras,
where the bone marrow compartment expressed an inap-
propriate MHC haplotype for presentation of OVA to
OT-I cells (10), proliferation was abolished (data not
shown). This latter point indicates that a bone marrow–
derived APC was responsible for capturing and cross-pre-
senting OVA released by cellular destruction.
To examine the kinetics of cross-presentation after cellu-
lar destruction, RIP-OVA
 
lo
 
 mice were treated with acti-
vated CTLs to cause islet damage and then injected with
CFSE-labeled naive OT-I cells either 1 or 4 d later. In pre-
vious studies we had shown that it takes 24 h for OT-I cells
to begin proliferating after exposure to cross-presented an-
tigen (11). Thus, we allowed the CFSE-labeled naive T
cells to remain in these mice for a total of 3 d after transfer
to ensure that there was enough time to adequately detect
proliferation. Mice were killed and their pancreatic (drain-
ing) and inguinal (nondraining) LNs examined for prolifer-
ating OT-I cells (Fig. 4). No proliferation was seen in the
pancreatic LNs from mice receiving CSFE-labeled cells on
day 1 after initiation of 
 
b
 
 cell damage (Fig. 4, 
 
G
 
 and 
 
H
 
),
whereas considerable proliferation was evident in the day 4
group (Fig. 4, 
 
C
 
 and 
 
D
 
). From these experiments, we can
Figure 3. Activated OT-I
cells cause diabetes when adop-
tively transferred into RIP-
OVAlo mice or RIP-OVAhi
mice. OT-I cells were activated
with antigen in vitro for 5 d and
then 107 cells were adoptively
transferred intravenously into
adult RIP-OVAlo ( solid line) or
RIP-OVAhi ( dashed line) mice.
These mice were then moni-
tored daily for induction of dia-
betes as measured by glucosuria.
Islet destruction was confirmed
by histological examination of pancreatic tissue sections from several of
these mice. These data represent the compilation of five experiments.
Figure 2. Secreted OVA is cross-presented in the draining LNs of the
pancreas when expressed at a sufficiently high dose. 5 3 106 OT-I cells
were labeled with CFSE (11) and adoptively transferred intravenously
into either RIP-OVAlo mice (A and B), RIP-OVAhi mice (C and D), or
negative littermates (data not shown). 3 d later, the pancreatic (A and C)
and inguinal (B and D) LN cells were analyzed by flow cytometry (11).
As previously reported (11), negative littermates did not induce prolifera-
tion of OT-I cells (data not shown). Histograms were gated on
CD81CFSE1 cells. 
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roughly estimate the minimum time necessary for antigen
to appear in LNs after OT-I cell-induced 
 
b
 
 cell damage.
Simply, since it takes at least 24 h for the cells to start pro-
liferating after exposure to cross-presented antigen (11),
then antigen must reach the LNs no earlier than day 3 after
induction of tissue damage based on the lack of prolifera-
tion found in Fig. 4 
 
G
 
, and no later than day 6 given the
proliferation shown in Fig. 4 
 
C.
Discussion
As previously reported, antigens expressed in peripheral
tissues can be captured by bone marrow–derived APCs,
processed via the cross-presentation pathway, and then pre-
sented in the draining LNs to naive CD81 T cells (10). In
this report, we show that peripheral tissue antigens must be
expressed at relatively high levels to be cross-presented
constitutively. When antigens were expressed at high
doses, as in RIP-OVAhi mice (Fig. 2), they were cross-pre-
sented in the draining LNs and caused activation and pro-
liferation of naive CD81 T cells. Antigen expression levels
below a certain threshold, as seen in RIP-OVAlo mice,
were ignored by naive CD81 T cells, which failed to pro-
liferate in the draining LNs (Fig. 2).
Here, we also show that antigen access to the cross-pre-
sentation pathway can result after cellular destruction by
CTL (Fig. 4). How CTL lysis allows antigen entry into this
pathway is unknown, but it has recently been reported that
apoptotic cells can be captured and presented by myeloid
dendritic cells (20). This raises the possibility that apoptosis
of target cells by activated CTLs may facilitate access to the
cross-presentation pathway.
One of the critical observations of this report is that al-
though lower dose antigens were unable to stimulate via
the cross-presentation pathway, they still directly sensitized
tissue (islet) cells, in which they were expressed, for recog-
nition by activated CTLs. However, the direct recognition
pathway is only available for recognition by activated
CTLs, since only activated CTLs will have the capacity to
leave the secondary lymphoid compartment and interact
with these tissues. Thus, there appear to be three categories
into which peripheral tissue antigens fall: category 1, those
that are expressed at high levels and can be both cross-pre-
sented to naive CTLs and directly seen by activated CTLs;
category 2, those that are expressed at lower concentrations
and are nonstimulatory via the cross-presentation pathway,
but can sensitize peripheral tissue cells for direct recogni-
tion by activated CTLs; and category 3, those antigens that
can never be seen by CTLs.
The importance of these categories becomes apparent
when we consider the physiological roles of the cross-pre-
sentation pathway. Recently, we provided evidence that
cross-presentation of self-antigens leads to peripheral dele-
tion of autoreactive CD81 T cells (11). We showed that
adoptively transferred OT-I cells were activated by cross-
presented tissue antigens in RIP-mOVA mice, leading to
proliferation and then deletion of the responding OT-I
cells. If, as we have shown (11), self-tolerance is a conse-
quence of cross-presentation of self-antigens, then only
those antigens expressed at levels sufficiently high to be
cross-presented will induce such tolerance. Thus, the idea
that peripheral antigens are ignored (21–23), may only ap-
ply to antigens that do not stimulate by cross-presentation,
i.e., category 2 antigens. High dose self-antigens (category
1) would induce deletional tolerance via the cross-presen-
tation pathway, whereas those lower dose antigens in cate-
gory 2 would be ignored by naive CTLs but still able to
sensitize peripheral tissues for recognition by activated
CTLs. Perhaps this explains why some model self-antigens
expressed by islet b cells were reported to induce tolerance
(11, 24, 25), whereas others were ignored (21–23). Analysis
of the effect of antigen dose on peripheral tolerance will be
the subject of a later report (Kurts, C., J.F.A.P. Miller, F.R.
Carbone, and W.R. Heath, manuscript in preparation).
The tolerance induced by cross-presented self-antigens
contrasts with the immunity seen when foreign antigens
were used to induce CTLs by cross-priming (2–5, 7–9, 13,
14). What determines whether tolerance or immunity is
Figure 4. Tissue destruction facilitates cross-presentation of low dose
antigens. RIP-OVAlo mice were either left untreated (A and B) or in-
jected with 5 3 106 OT-I cells activated as in Fig. 3 (C–H). 1 (G and H)
or 4 d (A–F) later, mice were injected with CFSE-labeled cells (either 5 3
106 naive OT-I cells [A–D, G, and H] or 2 3 106 B6 CD81 LN cells [E
and F]). After a further 3 d, the pancreatic (A, C, E, and G) and inguinal
(B, D, F, and H) LN cells were analyzed by flow cytometry. Histograms
were gated on CD81CFSE1 cells.413 Kurts et al. Brief Definitive Report
induced is unclear, but CD41 T cell help appears to be im-
portant (12, 14, 26). Since the cross-presentation pathway
is involved in both cross-tolerance and cross-priming, the
mechanisms by which antigens gain access to this pathway
is likely to affect both aspects. The focus of this pathway on
high dose antigens may direct CTLs immunity towards
cells producing large amounts of viral proteins, whereas the
ability to recognize antigens associated with tissue destruc-
tion may be important for responses to cytopathic viruses.
In summary, this report provides the first in vivo evi-
dence that cellular destruction can enhance access of pe-
ripheral antigens to the cross-presentation pathway. In ad-
dition, we show that high dose antigens are preferentially
cross-presented, although lower doses may still be of physi-
ological relevance by their ability to be directly presented
to activated CTLs entering peripheral tissues. Together,
these data lead to the conclusion that the cross-presentation
pathway is focused on high dose antigens or those released
during cellular destruction.
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